Exhibit 99.1 BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates 1 - $120.7 million in total third quarter revenue, comprised of$108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and$8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patien ...